Cargando…

Derivation of a Novel Scoring System Predicting High Platelet Reactivity on Prasugrel in Patients with Coronary Artery Disease

Aims: High platelet reactivity (HPR) has been associated with an increased risk of thrombotic events in patients undergoing percutaneous coronary intervention. HPR has been well examined in patients treated with clopidogrel; however, HPR on prasugrel is poorly investigated. Methods: Four prospective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saito, Yuichi, Nishi, Takeshi, Wakabayashi, Shinichi, Ohno, Yuji, Kitahara, Hideki, Ariyoshi, Noritaka, Kobayashi, Yoshio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623081/ https://www.ncbi.nlm.nih.gov/pubmed/34937827 http://dx.doi.org/10.5551/jat.63300

Ejemplares similares

Differential Impact of Clinical and Genetic Factors on High Platelet Reactivity in Patients with Coronary Artery Disease Treated with Clopidogrel and Prasugrel
por: Saito, Yuichi, et al.
Publicado: (2022)

Coronary Flow Reserve and Glycemic Variability in Patients with Coronary Artery Disease
por: Nishi, Takeshi, et al.
Publicado: (2020)

Relation of GRACE Risk Score to Coronary Lipid Core Plaques in Patients with Acute Coronary Syndrome
por: Sato, Takanori, et al.
Publicado: (2023)

Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis
por: Dai, Lulu, et al.
Publicado: (2022)

Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention
por: Kitahara, Hideki, et al.
Publicado: (2022)

Correction: Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention
por: Kitahara, Hideki, et al.
Publicado: (2023)

Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis
por: Wen, Mingxiang, et al.
Publicado: (2020)

Coronary Artery Perforation After Balloon Dilatation for Recurrent In-Stent Restenosis Inside the Double-Layered Previous Stents
por: Yamashita, Daichi, et al.
Publicado: (2023)

High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel
por: Geisler, Tobias, et al.
Publicado: (2015)

Relation of Elevated Serum Uric Acid Level to Endothelial Dysfunction in Patients with Acute Coronary Syndrome
por: Saito, Yuichi, et al.
Publicado: (2019)

Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study
por: Alexopoulos, Dimitrios, et al.
Publicado: (2015)

Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes
por: Ndrepepa, Gjin, et al.
Publicado: (2021)

Effects of Clopidogrel, Prasugrel and Ticagrelor on Microvascular Function and Platelet Reactivity in Patients With Acute Coronary Syndrome Undergoing Coronary Artery Stenting. A Randomized, Blinded, Parallel Group Trial
por: Schnorbus, Boris, et al.
Publicado: (2021)

Prognostic Factors of In-Hospital Mortality in Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock
por: Sato, Takanori, et al.
Publicado: (2022)

Validation of the Domestic High Bleeding Risk Criteria for Japanese Patients with Acute Myocardial Infarction
por: Matsumoto, Tadahiro, et al.
Publicado: (2023)

Impact of Denture Use on Ischemic and Bleeding Outcomes of Patients with Acute Myocardial Infarction
por: Yamashita, Daichi, et al.
Publicado: (2022)

Association between Platelet Count and Treatment Effect of Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
por: Koch, Tobias, et al.
Publicado: (2023)

Prasugrel for the treatment of patients with acute coronary syndrome
por: Marzot, Filippo, et al.
Publicado: (2009)

Clinical characteristics and outcomes of patients with chronic systemic inflammatory disease in acute myocardial infarction
por: Yaginuma, Hiroaki, et al.
Publicado: (2023)

Systemic Endothelial Function, Plasma Xanthine Oxidoreductase Activity, and Blood Pressure Variability in Patients with Stable Coronary Artery Disease
por: Hiraga, Takashi, et al.
Publicado: (2022)

Comparison of lower loading dose of prasugrel with conventional loading dose of prasugrel in Indian patients undergoing percutaneous coronary interventions
por: Kumari, Priti, et al.
Publicado: (2018)

Vasodilator-stimulated phosphoprotein (VASP) is not a major mediator of platelet aggregation, thrombogenesis, haemostasis, and antiplatelet effect of prasugrel in rats
por: Ito, Yusuke, et al.
Publicado: (2018)

Factors Associated with Impaired Resistive Reserve Ratio and Microvascular Resistance Reserve
por: Yamazaki, Tatsuro, et al.
Publicado: (2023)

ST-Segment Elevation Myocardial Infarction in a 32-Year-Old Man With a History of Incomplete Kawasaki Disease
por: Yamazaki, Tatsuro, et al.
Publicado: (2023)

Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation
por: Shimamatsu, Junichiro, et al.
Publicado: (2019)

Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor
por: Adamski, Piotr, et al.
Publicado: (2022)

Platelet reactivity expressed as a novel platelet reactivity score is associated with higher inflammatory state after coronary artery bypass grafting
por: Wilczyński, Mirosław, et al.
Publicado: (2019)

Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Norgard, Nicholas B, et al.
Publicado: (2009)

Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel
por: Motovska, Zuzana, et al.
Publicado: (2009)

Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel
por: LEADBEATER, P D M, et al.
Publicado: (2011)

Impact of Serum Uric Acid Level on Systemic Endothelial Dysfunction in Patients with a Broad Spectrum of Ischemic Heart Disease
por: Hiraga, Takashi, et al.
Publicado: (2021)

Efficacy of intravenous nicorandil for fractional flow reserve assessment: study protocol for a crossover randomised trial
por: Nishi, Takeshi, et al.
Publicado: (2016)

Feasibility of management of hemodynamically stable patients with acute myocardial infarction following primary percutaneous coronary intervention in the general ward settings
por: Tateishi, Kazuya, et al.
Publicado: (2020)

Prasugrel in critically ill patients
por: Schoergenhofer, Christian, et al.
Publicado: (2017)

Relation Between Cancer and Vasospastic Angina
por: Matsumoto, Tadahiro, et al.
Publicado: (2021)

Update on Antithrombotic Therapy after Percutaneous Coronary Intervention
por: Saito, Yuichi, et al.
Publicado: (2019)

Interactions of fentanyl with blood platelets and plasma proteins: platelet sensitivity to prasugrel metabolite is not affected by fentanyl under in vitro conditions
por: Bednarek, Radosław, et al.
Publicado: (2023)

Prasugrel, a Platelet P2Y(12) Receptor Antagonist, Improves Abnormal Gait in a Novel Murine Model of Thrombotic Hindlimb Ischemia
por: Ohno, Kousaku, et al.
Publicado: (2016)

Prasugrel, a new medicine for preventing blockages in the arteries
por: Wang, Zhi-Mei, et al.
Publicado: (2010)

Comparative Effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for Secondary Prophylaxis in Acute Coronary Syndrome: A Propensity Score‐Matched Cohort Study
por: Kumar, Arun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s0m7g42ei5pr8hd3sr9lpndrdi